Palo Alto Health Sciences appoints Joseph Perekupka as Chief Commercial Officer

Healthcare sales veteran brings substantial leadership and device commercialization expertise to Palo Alto Health Sciences, Inc.

KIRKLAND, WA. (September 25, 2019) – Palo Alto Health Sciences, Inc. (PAHS), whose product Freespira® is the only FDA-cleared digital therapeutic for treating panic attacks, panic related disorders, and PTSD is pleased to announce the addition of Joseph (Joe) Perekupka to its Senior Executive team as Chief Commercial Officer. In his newly appointed role, Joe will be driving the expansion of Freespira’s commercial, government and marketing operations.

Continue reading “Palo Alto Health Sciences appoints Joseph Perekupka as Chief Commercial Officer”

Palo Alto Health Sciences Obtains FDA-Clearance for Freespira in Treating Post-Traumatic Stress Disorder

Ninety-one percent of PTSD patients had significant reduction in PTSD Assessment Score and 50% of patients no longer met diagnostic criteria for PTSD six months post
Freespira treatment

Kirkland, WA (December 18, 2018) – Palo Alto Health Sciences, Inc. (PAHS) announced today that its flagship digital therapeutic, Freespira®, has been cleared by the FDA as a treatment option for patients diagnosed with post-traumatic stress disorder (PTSD).

Continue reading “Palo Alto Health Sciences Obtains FDA-Clearance for Freespira in Treating Post-Traumatic Stress Disorder”

Highmark Inc. Adds Coverage For Medical Innovations In Treatment Of Panic Attacks […]

PITTSBURGH, Pa. (Sept. 17, 2018) — A new, non-pharmaceutical treatment, Freespira, and non-invasive diagnostic technology, Heartflow FFRct (fractional flow reserve), were added to Highmark’s medical policy in 2018 following positive results from a program that fast-tracks medical innovations to the marketplace. Continue reading “Highmark Inc. Adds Coverage For Medical Innovations In Treatment Of Panic Attacks […]”

Multiple Studies Show Freespira® Eliminates Panic Attacks in 80% of Patients

50% Reduction in Health Costs One Year Post-Treatment Also Demonstrated

Danville, CA – (April 11 , 2018) – Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira® treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment. Continue reading “Multiple Studies Show Freespira® Eliminates Panic Attacks in 80% of Patients”

Palo Alto Health Sciences Names Amy Perry to Board of Directors

Danville, CA – (August 17, 2017) – Palo Alto Health Sciences, Inc. (PAHS), developer of the Freespira® treatment for panic attacks and panic disorder, today announced that Amy Perry, CEO of the Hospital Division and Senior Vice President of Integrated Care delivery at Atlantic Health System in New Jersey, will join its Board of Directors. Continue reading “Palo Alto Health Sciences Names Amy Perry to Board of Directors”

Palo Alto Health Sciences Partners with Silicon Valley TMS Integrated Clinical Neurosciences to Offer Freespira® Treatment for Panic Attacks and Panic Disorder

Danville, CA – (May 2, 2017) – Palo Alto Health Sciences, Inc. (PAHS), developer of the Freespira® treatment for panic attacks and other symptoms of panic disorder, today announced that it has partnered with Silicon Valley TMS, the leading San Francisco Bay Area provider of neuro-psychiatric services, to offer the Freespira Program. Continue reading “Palo Alto Health Sciences Partners with Silicon Valley TMS Integrated Clinical Neurosciences to Offer Freespira® Treatment for Panic Attacks and Panic Disorder”

Next Generation Freespira® System for Panic Attacks to be Unveiled at Anxiety and Depression Association of America Conference

Danville, CA – (April 4, 2017) – Palo Alto Health Sciences, Inc. (PAHS), developer of the Freespira® at-home treatment for panic attacks and panic disorder, today announced that the latest generation Freespira System will be debuted at the Anxiety and Depression Association of America’s Annual Conference April 6-9 in San Francisco. Sleeker and more ergonomic, the new Freespira handheld sensor provides quicker start-up and improved ease of use, enhancing the patient’s experience and adherence. As in prior designs, Freespira seamlessly uploads treatment data to a secure server for clinical review and monitoring, which facilitates patient and provider engagement. Continue reading “Next Generation Freespira® System for Panic Attacks to be Unveiled at Anxiety and Depression Association of America Conference”